The Association Between Meningioma and Breast Cancer

Degeneffe, Aurélie; Maertelaer, Viviane De; Witte, Olivier De; Lefranc, Florence

doi:10.1001/jamanetworkopen.2023.18620

Cited by 10 publications

(4 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, previous pregnancy does not appear to be an unequivocal risk factor for meningioma 9. Studies have also shown a link, albeit a weak one, between breast cancer and meningiomas 10…”

Section: Introductionmentioning

confidence: 94%

Use of progestogens and the risk of intracranial meningioma: national case-control study

Roland,

Neumann,

Hoisnard

et al. 2024

BMJ

View full text Add to dashboard Cite

Objective To assess the risk of intracranial meningioma associated with the use of selected progestogens. Design National case-control study. Setting French National Health Data System (ie, Système National des Données de Santé ). Participants Of 108 366 women overall, 18 061 women living in France who had intracranial surgery for meningioma between 1 January 2009 and 31 December 2018 (restricted inclusion periods for intrauterine systems) were deemed to be in the case group. Each case was matched to five controls for year of birth and area of residence (90 305 controls). Main outcome measures Selected progestogens were used: progesterone, hydroxyprogesterone, dydrogesterone, medrogestone, medroxyprogesterone acetate, promegestone, dienogest, and intrauterine levonorgestrel. For each progestogen, use was defined by at least one dispensation within the year before the index date (within three years for 13.5 mg levonorgestrel intrauterine systems and five years for 52 mg). Conditional logistic regression was used to calculate odds ratio for each progestogen meningioma association. Results Mean age was 57.6 years (standard deviation 12.8). Analyses showed excess risk of meningioma with use of medrogestone (42 exposed cases/18 061 cases (0.2%) v 79 exposed controls/90 305 controls (0.1%), odds ratio 3.49 (95% confidence interval 2.38 to 5.10)), medroxyprogesterone acetate (injectable, 9/18 061 (0.05%) v 11/90 305 (0.01%), 5.55 (2.27 to 13.56)), and promegestone (83/18 061 (0.5%) v 225/90 305 (0.2 %), 2.39 (1.85 to 3.09)). This excess risk was driven by prolonged use (≥one year). Results showed no excess risk of intracranial meningioma for progesterone, dydrogesterone, or levonorgestrel intrauterine systems. No conclusions could be drawn concerning dienogest or hydroxyprogesterone because of the small number of individuals who received these drugs. A highly increased risk of meningioma was observed for cyproterone acetate (891/18 061 (4.9%) v 256/90 305 (0.3%), odds ratio 19.21 (95% confidence interval 16.61 to 22.22)), nomegestrol acetate (925/18 061 (5.1%) v 1121/90 305 (1.2%), 4.93 (4.50 to 5.41)), and chlormadinone acetate (628/18 061 (3.5%) v 946/90 305 (1.0%), 3.87 (3.48 to 4.30)), which were used as positive controls for use. Conclusions Prolonged use of medrogestone, medroxyprogesterone acetate, and promegestone was found to increase the risk of intracranial meningioma. The increased risk associated with the use of injectable medroxyprogesterone acetate, a widely used contraceptive, and the safety of levonorgestrel intrauterine systems are important new findings.

show abstract

“…However, previous pregnancy does not appear to be an unequivocal risk factor for meningioma 9. Studies have also shown a link, albeit a weak one, between breast cancer and meningiomas 10…”

Section: Introductionmentioning

confidence: 94%

Use of progestogens and the risk of intracranial meningioma: national case-control study

Roland,

Neumann,

Hoisnard

et al. 2024

BMJ

View full text Add to dashboard Cite

show abstract

“…It has been suggested that the difference in incidence is related to the different levels of hormones between males and females, because meningiomas are known to have progesterone and oestrogen receptors that can influence the response of the tumour to sex hormones [47,51,52]. Other studies have focused on the connection between breast cancer and meningioma in relation to hormone levels because breast cancer has wellestablished hormonal involvement and patients with meningiomas are more likely to develop breast cancer [53]. Other studies conducted in females who received cyproterone acetate (a synthetic progestin) to treat severe cases of hirsutism suggested that this hormonal therapy increases the incidence of meningioma [54].…”

Section: Meningiomamentioning

confidence: 99%

Modelling Meningioma Using Organoids: A Review of Methodologies and Applications

López Vásquez,

Gray,

Henry

et al. 2023

Organoids

View full text Add to dashboard Cite

Meningiomas are the most common tumours of the central nervous system. According to the World Health Organization (WHO), this disease is classified into three different grades: 80% of meningioma patients present with benign grade I tumours, while less than 2% present with malignant grade III meningiomas. Despite affecting thousands of people worldwide, much remains unknown about this disease, and the development of systemic treatments is still far behind in comparison to other types of tumours. Therefore, forming 3D structures (spheroids and organoids) could facilitate research on the mechanisms of formation, proliferation, migration, and invasion of these, for the most part, benign tumours, while also helping in the process of drug development. To date, there are three published methods for the formation of meningioma organoids primarily derived from patient tissue samples. Organoids offer many advantages in the development of treatments because they recapitulate the cellular complexity within tumours. These new methodological advances could open a substantial number of possibilities for the further characterisation and treatment of meningiomas. This review includes an overview of the disease and a description and comparison of established protocols for meningioma organoid formation.

show abstract

“…Meningiomas originate from arachnoid cap cells, are usually estimated to grow 2–4 mm/year and are slightly more common in females [ 2 – 4 ]. Several risk factors for meningioma development have been investigated, with age, radiation and sex hormones being most commonly reported as elevating the risk of the disease [ 5 , 6 ], while smoking, hypertension and the metabolic syndrome still being mostly inconclusive as risk factors [ 2 – 4 ]. According to the current WHO classification [ 7 ], roughly 80% of meningiomas are considered grade 1 lesions, with a 10-year overall survival rate of up to 90%.…”

Section: Introductionmentioning

confidence: 99%

Chronic hyperglycemia and intracranial meningiomas

Orešković,

Madero Pohlen,

Cvitković

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Meningiomas are among the most common primary tumors of the central nervous system. Previous research into the meningioma histological appearance, genetic markers, transcriptome and epigenetic landscape has revealed that benign meningiomas significantly differ in their glucose metabolism compared to aggressive lesions. However, a correlation between the systemic glucose metabolism and the metabolism of the tumor hasn’t yet been found. We hypothesized that chronic levels of glycaemia (approximated with glycated hemoglobin (HbA1c)) are different in patients with aggressive and benign meningiomas. The study encompassed 71 patients with de novo intracranial meningiomas, operated on in three European hospitals, two in Croatia and one in Spain. Our results show that patients with WHO grade 2 meningiomas had significantly higher HbA1c values compared to patients with grade 1 lesions (P = 0.0290). We also found a significant number of patients (19/71; 26.7%) being hyperglycemic, harboring all the risks that such a condition entails. Finally, we found a significant correlation between our patients’ age and their preoperative HbA1c levels (P = 0.0008, ρ(rho) = 0.388), suggesting that older meningioma patients are at a higher risk of having their glycaemia severely dysregulated. These findings are especially important considering the current routine and wide-spread use of corticosteroids as anti-edematous treatment. Further research in this area could lead to better understanding of meningiomas and have immediate clinical impact.

show abstract

The Association Between Meningioma and Breast Cancer

Cited by 10 publications

References 67 publications

Use of progestogens and the risk of intracranial meningioma: national case-control study

Use of progestogens and the risk of intracranial meningioma: national case-control study

Modelling Meningioma Using Organoids: A Review of Methodologies and Applications

Chronic hyperglycemia and intracranial meningiomas

Contact Info

Product

Resources

About